Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.2500
+0.0210 (9.17%)
At close: Jun 24, 2025, 4:00 PM
0.2578
+0.0078 (3.12%)
Pre-market: Jun 25, 2025, 6:01 AM EDT

Company Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patient populations with unmet medical needs.

The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.

Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.

The company’s lead product candidate, Reqorsa gene therapy (quaratusugene ozeplasmid), for the treatment of non-small and small cell lung cancer.

It is also developing diabetes gene therapy, a novel infusion process that uses an adeno-associated virus vector to deliver Pdx1 and MafA genes directly to the pancreatic duct; GPX-002 for Type 1 diabetes transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

It has license agreement from the University of Pittsburgh of the Commonwealth System of Higher Education (University of Pittsburgh) multiple technologies relating to the development of a gene therapy product for both Type 1 and Type 2 diabetes.

Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex, Inc.
Genprex logo
Country United States
Founded 2009
IPO Date Mar 29, 2018
Industry Biotechnology
Sector Healthcare
Employees 15
CEO Ryan Confer

Contact Details

Address:
3300 Bee Cave Road, Suite 650-227
Austin, Texas 78746
United States
Phone 877 774 4679
Website genprex.com

Stock Details

Ticker Symbol GNPX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001595248
CUSIP Number 372446104
ISIN Number US3724462037
Employer ID 90-0772347
SIC Code 2834

Key Executives

Name Position
Ryan M. Confer M.S. President, Chief Executive Officer, Chief Financial Officer and Director
Dr. Mark S. Berger M.D. Chief Medical Officer
David M. Schloss Senior Vice President of Human Resources
Thomas C. Gallagher Esq. Senior Vice President of Intellectual Property and Licensing
Dr. Suzanne Thornton-Jones Ph.D. Senior Vice President of Regulatory Affairs and Quality
Dr. Jack A. Roth F.A.C.S., M.D. Chairman of Scientific and Medical Advisory Board

Latest SEC Filings

Date Type Title
Jun 24, 2025 8-K Current Report
Jun 23, 2025 8-K Current Report
Jun 17, 2025 EFFECT Notice of Effectiveness
Jun 17, 2025 424B3 Prospectus
Jun 11, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Jun 11, 2025 8-K Current Report
Jun 9, 2025 8-K Current Report
May 14, 2025 S-1 General form for registration of securities under the Securities Act of 1933
May 12, 2025 10-Q Quarterly Report
May 7, 2025 8-K Current Report